Atossa Therapeutics (ATOS) Interest & Investment Income (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Interest & Investment Income of $309000.0 for Q1 2026, down 57.08% year-over-year from $720000.0 in Q1 2025, and down 30.09% quarter-over-quarter from $442000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Interest & Investment Income (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Interest & Investment Income for 10 consecutive years, with $309000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 57.08% year-over-year to $309000.0; the TTM figure through Mar 2026 stood at $2.0 million (down 45.86% YoY), while the FY2025 annual figure was $2.4 million, down 41.31% from the prior year.
- Interest & Investment Income retreated to $309000.0 in Q1 2026 per ATOS's latest filing, from $442000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.3 million in Q3 2023 and bottomed at $1000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $703176.5 across 5 years, with a median of $720000.0 in 2025.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 84900.0% — and 2026, when it plunged 57.08%.
- Atossa Therapeutics' Interest & Investment Income stood at $670000.0 in 2022, then jumped by 84.48% to $1.2 million in 2023, then sank by 32.28% to $837000.0 in 2024, then slumped by 47.19% to $442000.0 in 2025, then plunged by 30.09% to $309000.0 in 2026.
- Business Quant data shows ATOS's Interest & Investment Income at $309000.0 in Q1 2026, $442000.0 in Q4 2025, and $570000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 227,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 227,000.00 |
| Mar 31, 2026 | 309,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 570,000.00 |
| Jun 30, 2025 | 645,000.00 |
| Mar 31, 2025 | 720,000.00 |
| Dec 31, 2024 | 837,000.00 |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 1.24 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 983,000.00 |
| Mar 31, 2023 | 850,000.00 |
| Dec 31, 2022 | 670,000.00 |
| Sep 30, 2022 | 194,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2015 | 279.00 |
| Dec 31, 2014 | 106.00 |